| LG LIFE SCIENCES, LTD. Patent applications |
| Patent application number | Title | Published |
|---|
| 20130059751 | GENE FAMILY (LBFL313) ASSOCIATED WITH PANCREATIC CANCER - The invention relates generally to the changes in gene expression in human pancreatic adenocarcinoma. The invention relates specifically to a human gene family which is differentially expressed in cancerous pancreatic tissues compared to corresponding non-cancerous pancreatic tissues. | 03-07-2013 |
| 20110224219 | MELANOCORTIN RECEPTOR AGONISTS - The present invention relates to a compound having a good agonistic activity to melanocortin receptor, or pharmaceutically acceptable salt or isomer thereof, and an agonistic composition for melanocortin receptor comprising the same as an active ingredient. | 09-15-2011 |
| 20110201554 | HFSH AQUEOUS FORMULATION - Provided is an aqueous formulation of a human follicle stimulating hormone (hFSH) which is stabilized to maintain the activity of hFSH for a prolonged period of time. The formulation of the present invention is an aqueous formulation comprising a therapeutically effective amount of hFSH stabilized in a phosphate buffer containing glycine, methionine and a non-ionic surfactant, preferably polysorbate 20, which is capable of maintaining the activity of hFSH for an extended period of time. | 08-18-2011 |
| 20110166356 | METHOD FOR PREPARING MONTELUKAST SODIUM SALTS - Disclosed is a method for preparing a montelukast sodium salt of Formula 1. The method includes coupling a methanesulfonyl compound of Formula 2 below with a compound of Formula 3 below in the presence of a bistrimethylsilylamide alkali metal salt, further adding an alkali metal base thereto and hydrolyzing the mixture by heating to prepare a compound of Formula 4 below, reacting the compound of Formula 4 with 4-tert-butylcyclohexylamine, followed by purification, to prepare an amine salt of Formula 5, and converting the amine salt of Formula 5 into a sodium salt. | 07-07-2011 |
| 20110166121 | FUSED HETEROCYCLIC COMPOUND - The present invention relates to a fused heterocyclic compound having the Formula 1, which is useful as a platelet aggregation inhibitor, a method for preparing the same, and a pharmaceutical composition for inhibiting platelet aggregation comprising the same. | 07-07-2011 |
| 20100274013 | DIPEPTIDYL PEPTIDASE-IV INHIBITING COMPOUNDS, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS ACTIVE AGENT - Disclosed herein are novel compounds of Formula (1) as defined in the specification having excellent inhibitory activity against dipeptidyl peptidase-IV (DPP-IV), methods of preparing the same and pharmaceutical compositions comprising the same as an active agent. | 10-28-2010 |
| 20100267708 | GLUCOKINASE ACTIVATORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE INGREDIENT - The present invention relates to new compounds of formula (1) exhibiting excellent activity for glucokinase, and pharmaceutical compositions comprising the same as an active ingredient. | 10-21-2010 |
| 20100210647 | INDOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS - The present invention relates to new indole compounds, pharmaceutically acceptable salts or isomers thereof which are useful for the prevention or treatment of cellular necrosis and necrosis-associated diseases. The present invention also relates to a method and a composition for the prevention or treatment of cellular necrosis and necrosis-associated diseases, comprising said indole compounds as an active ingredient. | 08-19-2010 |
| 20100197673 | INDOLE AND INDAZOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS - The present invention relates to indole or indazole compounds, pharmaceutically acceptable salts or isomers thereof which are useful for the prevention or treatment of cellular necrosis and necrosis-associated diseases. The present invention also relates to a method and a composition for the prevention or treatment of cellular necrosis and necrosis-associated diseases, comprising said indole or indazole compounds as an active ingredient. | 08-05-2010 |
| 20100173284 | Method for Detection of HCV at the Real Time PCR with Intercalating Dye - The present invention relates to a composition for detection of HCV by a single step reaction, comprising a specific primer and probe. In particular, the present invention relates to a composition for detection of HCV by a single step reaction, comprising the primer sequences of SEQ ID NOs:1 and 2; a composition for detection of HCV by a single step reaction, comprising both the primer sequences and a probe of SEQ ID NOs:5 or 9; a method for detecting HCV by a single step reaction, comprising the steps of obtaining a sample from a subject, and amplifying and detecting HCV using the primer and probe; and a kit comprising the primer and probe, in which the HCV detection method is characterized by a single step reaction. | 07-08-2010 |
| 20100120843 | PHARMACEUTICAL COMPOSITION FOR TREATING ALCOHOL-INDUCED LIVER INJURY COMPRISING (4S,5S)-5-FLUOROMETHYL-5-HYDROXY-4-(AMINO)-DIHYDROFURAN-2-ONE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF - The present invention relates to a pharmaceutical composition for treating alcohol-induced liver injury comprising (4S,5S)-5-fluoromethyl-5-hydroxy-4-({[(5R)-5-isopropyl-3-(isoquinolin-1-yl)-4,5-dihydro-5-isoxazolyl]carbonyl}amino)-dihydrofuran-2-one or pharmaceutically acceptable salt thereof, and a use thereof. | 05-13-2010 |
| 20100041661 | CASPASE INHIBITORS BASED ON PYRIDAZINONE SCAFFOLD - The present invention relates to a pyridazinone derivative which can be used as a caspase inhibitor, process for the preparation thereof, and pharmaceutical composition for inhibiting caspase comprising the same. | 02-18-2010 |
| 20100036158 | NOVEL PROCESS FOR PREPARING 3-AMINO-5-FLUORO-4-DIALKOXYPENTANOIC ACID ESTER - The present invention relates to a novel process for the production of 3-amino-5-fluoro-4-dialkoxypentanoic acid ester used in the precursor of 3-amino-5-fluoro-4-oxopentanoic acid, represented by the following formula (1): wherein R1 and R2 are as defined in the Description. | 02-11-2010 |
| 20100016376 | CASPASE INHIBITORS BASED ON PYRIDONE SCAFFOLD - The present invention relates to a pyridone derivative which can be used as a caspase inhibitor, process for the preparation thereof, and pharmaceutical composition for inhibiting caspase comprising the same. | 01-21-2010 |
| 20090325904 | MALEIC ACID MONOSALT OF ANTIVIRAL AGENT AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME - The present invention relates to 3-[({1-[(2-amino-9H-purin-9-yl)methyl]cyclopropyl}oxy)methyl]-8,8-dimethyl-3,7-dioxo-2,4,6-trioxa-3λ5-phosphanon-1-yl-pivalate maleic acid monosalt, and pharmaceutical composition containing the same. | 12-31-2009 |
| 20090291959 | CASPASE INHIBITORS BASED OF PYRIDAZINONE SCAFFOLD - The present invention relates to a pyridazinone derivative which can be used as a caspase inhibitor, process for the preparation thereof, and pharmaceutical composition for inhibiting caspase comprising the same. | 11-26-2009 |
| 20090197347 | IMMUNOASSAY FOR PLASMODIUM FALCIPARUM AND ASSAY DEVICE USED THEREFOR - Disclosed are an immunoassay of | 08-06-2009 |
| 20090188000 | GENE FAMILY (LBFL313) ASSOCIATED WITH PANCREATIC CANCER - The invention relates generally to the changes in gene expression in human pancreatic adenocarcinoma. The invention relates specifically to a human gene family which is differentially expressed in cancerous pancreatic tissues compared to corresponding non-cancerous pancreatic tissues. | 07-23-2009 |
| 20090181050 | Manufacturing Method of Combined Vaccine - The present invention relates to a method for manufacturing a combined vaccine capable of concurrently preventing multiple diseases such as diphtheria, tetanus, pertussis, and hepatitis B which should be prevented in an infant. The method for manufacturing a combined vaccine according to the present invention includes the steps of independently adsorbing each protective antigen to an adsorbent of a aluminum hydroxide gel with respect to various diseases such as diphtheria, tetanus, pertussis, and hepatitis B which should be prevented in the infants, and combining each protective antigen adsorbed to the adsorbent after the adsorption. In the present invention, it is possible to concurrently prevent multiple diseases such as diphtheria, tetanus, pertussis, and hepatitis B which should be prevented in the infant using a combined vaccine manufactured according to the present invention. | 07-16-2009 |
| 20080260654 | Sustained Release Composition of Protein Drug - Disclosed is a sustained release composition of a protein drug. The composition comprises a carrier substrate and a protein drug incorporated in the carrier substrate. The carrier substrate is consisting essentially of a hyaluronic acid or its salts, an amino acid, and a polyalkyl oxide. | 10-23-2008 |
